Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?

Introduction: Welcome to the future?

Date

27 Sep 2019

Session

Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?

Presenters

Joaquim Bellmunt

Authors

J. Bellmunt

Author affiliations

  • Medical Oncology Department, Harvard Medical School, 2115 - Boston/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings